Pharmaceuticals

For families battling Duchenne, treatment is a daily trade-off. Now, a new drug class promises to ease this burden, signaling a new era for rare disease care.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

A new deal to develop cancer drugs reveals a seismic shift: China is no longer just a market, but a core engine in a new global innovation network.

Octozi's $3M funding for its 'agentic AI' promises to slash drug development costs and time. But can algorithms be trusted with our most critical medical data?

Known for its athletic tape, KT is making a strategic leap into the crowded OTC pain relief aisle. Is this a brilliant brand extension or a risky bet?

Cytokinetics is set to unveil groundbreaking data for aficamten, a therapy that could become the first-ever approved treatment for non-obstructive HCM.

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

With a major FDA decision pending, Aquestive Therapeutics pitches its game-changing anaphylaxis film, Anaphylm, to Wall Street's top healthcare investors.

The FDA has fast-tracked mitapivat for sickle cell disease, offering new hope for patients. But a closer look reveals the high stakes of this strategy.

Saol Therapeutics' NDA resubmission isn't just a second chance; it's a calculated maneuver signaling a new playbook for navigating the FDA in rare disease.

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

A UK spinout just raised £2M for an eye-drop that becomes a healing bandage on contact. This could disrupt a $12B market and offer hope for rare diseases.

With a promising osteoarthritis drug in late-stage trials, Levicept hires a CFO known for Nasdaq listings and M&A, signaling a major financial move.

Aligos Therapeutics secures a key partnership and regulatory fast-track in China, signaling a major financial and clinical validation for its novel HBV drug.

In an era of fleeting sponsorships, one pharma giant's three-decade investment in sportsmanship offers a powerful blueprint for building sustainable brand trust.

As Genomma Lab prepares its Q2 2026 earnings call, investors are watching if its famed operational network can navigate a weak Mexican market and margin pressures.

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

Shilpa Medicare and Orion Corp. partner on a nivolumab biosimilar, challenging Big Pharma and promising affordable access to a vital cancer immunotherapy.

A new $200K award isn't just a grant; it's a strategic bet on systems engineering to fix a diagnostic pathway where 70% of lung cancer cases are found too late.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.